drugset
drugset / Trial / NCT00363831

Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

NCT00363831 ↗

Phase 2 Unknown 42 enrolled The University of Hong Kong
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary: * To evaluate the efficacy of capecitabine in combination with oxaliplatin (XELOX) in terms of overall response rate (based on RECIST criteria) in patients with metastatic NPC without prior chemotherapy for relapse. Secondary: * To evaluate the efficacy profile of oxaliplatin (XELOX) in patients with metastatic NPC in terms of time to progression of disease, survival time, duration of response and complete response rate. * To study the safety and tolerability of the regimen in patients with metastatic NPC.

Timeline

Start
2006-07
Primary completion
2009-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 130 mg/m2 Other

Indications

nasopharyngeal carcinoma